Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

(2021) Mary B. Daly et al.   Journal of the National Comprehensive Cancer Network

Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR

(2021) Nandini Dey et al.   Cancers

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis

(2021) Francesco Schettini et al.   Cancers

LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study

(2021) S.A. Hurvitz et al.   ANNALS OF ONCOLOGY

Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).

(2020) Qamar J. Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor–Positive Metastatic Breast Cancer

(2020) Jinming Li et al.   JAMA Network Open

Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: A network meta-analysis

(2019) Tingting Zhang et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis

(2019) Qianqian Guo et al.   Targeted Oncology

Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer

(2019) Lorenzo Rossi et al.   Clinical Breast Cancer

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer

(2019) Sara A. Hurvitz et al.   CLINICAL CANCER RESEARCH

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

(2019) Aleix Prat et al.   LANCET ONCOLOGY

Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis

(2018) Rajeev Ayyagari et al.   CURRENT MEDICAL RESEARCH AND OPINION

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

(2018) Luca Gianni et al.   LANCET ONCOLOGY

CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials

(2018) Carlo Messina et al.   BREAST CANCER RESEARCH AND TREATMENT

CDK4/6 inhibitors as neoadjuvant treatment in breast cancer—what can we learn?

(2018) M Brandão et al.   ANNALS OF ONCOLOGY

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

(2018) P Cottu et al.   ANNALS OF ONCOLOGY

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial

(2018) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value

(2017) Louis W C Chow et al.   ENDOCRINE-RELATED CANCER

The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis

(2017) Xianyu Chen et al.   Future Oncology

Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis

(2017) Lun Li et al.   Future Oncology

Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer

(2017) Miaomiao Tao et al.   MEDICINE

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study

(2016) G. Curigliano et al.   BREAST

PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

(2016) Charlotte Fribbens et al.   JOURNAL OF CLINICAL ONCOLOGY

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

(2016) Laura M. Spring et al.   JAMA Oncology

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer

(2015) S. E. Wardell et al.   CLINICAL CANCER RESEARCH

The Role of CDK4/6 Inhibition in Breast Cancer

(2015) C. G. Murphy et al.   ONCOLOGIST

Control of cell cycle transcription during G1 and S phases

(2013) Cosetta Bertoli et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

(2012) E. Alba et al.   ANNALS OF ONCOLOGY

Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy

(2012) Nehmat Houssami et al.   EUROPEAN JOURNAL OF CANCER

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

(2011) M. Dowsett et al.   JNCI-Journal of the National Cancer Institute

ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

(2011) T. W. Miller et al.   Cancer Discovery

Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial

(2009) John A. Olson et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS